Shared on 06 Nov 25

YPSN: Demand for Injectables Will Drive Future Earnings and Market Performance

Analysts have made no change to Ypsomed Holding’s fair value target, maintaining it at CHF 421.59. Recent research highlights both strong growth prospects in the injectables market and mixed sentiment following recent coverage changes.

Shared on 22 Oct 25

Fair value Decreased 1.94%

Analysts Revise Ypsomed Target Downward Amid Mixed Views on Growth and Margins

The analyst consensus price target for Ypsomed Holding has been revised downward by CHF 8.33 to CHF 421.59, as analysts cite slightly moderated growth prospects and profit margins. This comes despite continued optimism about the company's leadership in the high-growth injectables market.

Shared on 08 Oct 25

Fair value Decreased 4.33%

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

Analysts have lowered their fair value estimate for Ypsomed Holding from CHF 449.37 to CHF 429.92. They cite a more cautious outlook due to softer revenue growth expectations and increased discount rates, despite optimism about the company's leading role in the injectables market.

Shared on 23 Sep 25

Fair value Decreased 3.00%

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

Analyst sentiment on Ypsomed Holding has turned more cautious, citing diverging views on the sustainability of recent growth and transformation despite ongoing demand in injectables, resulting in a lowered consensus price target from CHF463.26 to CHF449.37. Analyst Commentary Bullish analysts highlight Ypsomed's leading position in the high-growth injectable market.

Shared on 05 Sep 25

Fair value Increased 1.69%

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

Ypsomed Holding’s analyst price target has been revised upward to CHF463.26 as the company consolidates its leadership in the high-growth injectables market following strategic divestitures and a sharpened operational focus. Analyst Commentary The company has established a leadership position in the high-growth injectable market.

Shared on 01 May 25

Fair value Decreased 7.95%

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

Shared on 23 Apr 25

Fair value Decreased 3.67%

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

AnalystConsensusTarget has decreased profit margin from 28.4% to 24.7%.

Shared on 17 Apr 25

Fair value Decreased 1.48%